pembrolizumab,enfortumab vedotin
merck,astellas,seagen
[' vedo', 'pembro', 'enfortumab', 'urothelial', 'blcsm']
the combination of enfortumab vedotin plus pembrolizumab led to a confirmed overall response rate of 64.5% in patients with metastatic urothelial cancer. #blcsm #esmo2022 | 
Oncology news and insights from leading researchers and cancer centers.